Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conheal is a preservative-free, inorganic salt-free, unit-dose artificial tear formulation containing isotonic glycerol and 0.015% sodium hyaluronate. Developed by Pannonpharma Ltd, it is primarily indicated for the treatment of dry eye disease and severe conjunctivochalasis. The mechanism involves the water-retention properties of hyaluronic acid and the lubricating and osmoprotective effects of glycerol. Clinical studies have demonstrated that regular use can significantly reduce the severity of Lid-Parallel Conjunctival Folds (LIPCOF), potentially providing a conservative alternative to surgical intervention for conjunctivochalasis. The formulation is designed to be infection-free for up to 12 hours after opening.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glycerol + sodium hyaluronate.